Open AccessAssociation of insulin treatment with gastric residue during an esophagogastroduodenoscopy
Author(s) -
Kobori Toshiko,
Onishi Yukiko,
Iwamoto Masahiko,
Kubota Tetsuya,
Kikuchi Takako,
Tahara Tazu,
Takao Toshiko,
Fujiwara Hiroaki,
Yoshida Yoko,
Kasuga Masato
Publication year - 2022
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13665
Subject(s) - esophagogastroduodenoscopy , medicine , diabetes mellitus , glycated hemoglobin , glycemic , retrospective cohort study , insulin , cohort , gastroenterology , type 2 diabetes , endocrinology , endoscopy
The purpose of this study was to investigate the association of glycemic control and diabetes treatment to gastric residue observed during an esophagogastroduodenoscopy. Among 6,592 individuals who had esophagogastroduodenoscopy at our clinic between 2003 and 2019, we retrospectively and longitudinally identified those who had gastric residue during an esophagogastroduodenoscopy. Other data collected were age, sex, diagnosis of diabetes, glycated hemoglobin and diabetes medication. Cox proportional hazards models were used to assess the association of these data with the occurrence of gastric residue. To the best of our knowledge, this is the first retrospective cohort study finding that undergoing insulin treatment is a risk factor for gastric residue independent of age, sex and diabetes or glycated hemoglobin.